Prognostic implications of cumulative dosing in total therapy 3

Documenti analoghi

• Total Therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide, and dexamethasone, relevant to all phases of therapy
  di: van Rhee, Frits, et al.
  Pubblicazione: (2010)
• Immunoglobulin isotypes in multiple myeloma: laboratory correlates and prognostic implications in total therapy protocols
  di: Nair, Bijay, et al.
  Pubblicazione: (2008)
• Prognostic implications of serial 18-fluoro-deoxyglucose emission tomography in multiple myeloma treated with total therapy 3
  di: Usmani, Saad Z., et al.
  Pubblicazione: (2013)
• Barlogie B, Crowley J. Prognostic implications of cumulative dosing in total therapy 3. Blood. 2012;120(16):3383-3385.
  Pubblicazione: (2013)
• Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2
  di: Pineda-Roman, Mauricio, et al.
  Pubblicazione: (2008)